VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | Nivo + ipi in RCC: OMNIVORE

Rana R. McKay, MD, UC San Diego Health, La Jolla, CA, USA, highlights data coming from the OMNIVORE study (NCT03203473). This phase II reponse-based study looked at the optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter